DongKook Pharmaceutical Co., Ltd.

KOSDAQ:A086450 Stock Report

Market Cap: ₩724.5b

DongKook Pharmaceutical Future Growth

Future criteria checks 2/6

DongKook Pharmaceutical is forecast to grow earnings and revenue by 16.2% and 9.7% per annum respectively. EPS is expected to grow by 15.7% per annum. Return on equity is forecast to be 10.6% in 3 years.

Key information

16.2%

Earnings growth rate

15.7%

EPS growth rate

Pharmaceuticals earnings growth33.8%
Revenue growth rate9.7%
Future return on equity10.6%
Analyst coverage

Low

Last updated19 Apr 2024

Recent future growth updates

Recent updates

We Think DongKook Pharmaceutical (KOSDAQ:086450) Can Stay On Top Of Its Debt

May 06
We Think DongKook Pharmaceutical (KOSDAQ:086450) Can Stay On Top Of Its Debt

DongKook Pharmaceutical Co., Ltd. (KOSDAQ:086450) Vies For A Place In Your Dividend Portfolio: Here's Why

Apr 06
DongKook Pharmaceutical Co., Ltd. (KOSDAQ:086450) Vies For A Place In Your Dividend Portfolio: Here's Why

How Much Of DongKook Pharmaceutical Co., Ltd. (KOSDAQ:086450) Do Insiders Own?

Mar 15
How Much Of DongKook Pharmaceutical Co., Ltd. (KOSDAQ:086450) Do Insiders Own?

The DongKook Pharmaceutical (KOSDAQ:086450) Share Price Has Gained 136%, So Why Not Pay It Some Attention?

Feb 28
The DongKook Pharmaceutical (KOSDAQ:086450) Share Price Has Gained 136%, So Why Not Pay It Some Attention?

DongKook Pharmaceutical Co., Ltd.'s (KOSDAQ:086450) Stock Is Going Strong: Is the Market Following Fundamentals?

Feb 14
DongKook Pharmaceutical Co., Ltd.'s (KOSDAQ:086450) Stock Is Going Strong: Is the Market Following Fundamentals?

DongKook Pharmaceutical (KOSDAQ:086450) Seems To Use Debt Quite Sensibly

Feb 01
DongKook Pharmaceutical (KOSDAQ:086450) Seems To Use Debt Quite Sensibly

DongKook Pharmaceutical Co., Ltd. (KOSDAQ:086450) Shares Could Be 47% Below Their Intrinsic Value Estimate

Jan 19
DongKook Pharmaceutical Co., Ltd. (KOSDAQ:086450) Shares Could Be 47% Below Their Intrinsic Value Estimate

The Attractive Combination That Could Earn DongKook Pharmaceutical Co., Ltd. (KOSDAQ:086450) A Place In Your Dividend Portfolio

Jan 06
The Attractive Combination That Could Earn DongKook Pharmaceutical Co., Ltd. (KOSDAQ:086450) A Place In Your Dividend Portfolio

DongKook Pharmaceutical Co., Ltd. (KOSDAQ:086450) Looks Like A Good Stock, And It's Going Ex-Dividend Soon

Dec 24
DongKook Pharmaceutical Co., Ltd. (KOSDAQ:086450) Looks Like A Good Stock, And It's Going Ex-Dividend Soon

With EPS Growth And More, DongKook Pharmaceutical (KOSDAQ:086450) Is Interesting

Dec 21
With EPS Growth And More, DongKook Pharmaceutical (KOSDAQ:086450) Is Interesting

What Kind Of Investors Own Most Of DongKook Pharmaceutical Co., Ltd. (KOSDAQ:086450)?

Dec 08
What Kind Of Investors Own Most Of DongKook Pharmaceutical Co., Ltd. (KOSDAQ:086450)?

The DongKook Pharmaceutical (KOSDAQ:086450) Share Price Is Up 177% And Shareholders Are Boasting About It

Nov 23
The DongKook Pharmaceutical (KOSDAQ:086450) Share Price Is Up 177% And Shareholders Are Boasting About It

Earnings and Revenue Growth Forecasts

KOSDAQ:A086450 - Analysts future estimates and past financials data (KRW Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2026981,60072,300N/A73,8001
12/31/2025893,80073,10075,00076,1502
12/31/2024810,50055,30054,20070,8001
12/31/2023730,99447,1752,20341,793N/A
9/30/2023709,54347,474-4,83438,961N/A
6/30/2023692,79447,1576,55041,667N/A
3/31/2023676,77253,2307,39043,763N/A
12/31/2022661,64752,896-11,06440,909N/A
9/30/2022645,74458,943-2,67345,738N/A
6/30/2022631,06555,611-12,49448,082N/A
3/31/2022615,97450,919-16,17049,477N/A
12/31/2021594,19350,345-5,02244,654N/A
9/30/2021585,74043,9451,63947,422N/A
6/30/2021588,36052,48425,34360,698N/A
3/31/2021572,39154,5155,61648,930N/A
12/31/2020559,10355,92517,81459,108N/A
9/30/2020544,68563,50219,85965,202N/A
6/30/2020520,46961,56913,24459,474N/A
3/31/2020502,39060,36038,67968,633N/A
12/31/2019482,28056,31244,37769,483N/A
9/30/2019456,23053,797-13,02360,123N/A
6/30/2019436,29350,618-28,59849,945N/A
3/31/2019418,58349,157-40,69532,790N/A
12/31/2018400,80746,949-42,32433,209N/A
9/30/2018391,80145,6958,92530,618N/A
6/30/2018378,38842,87224,48036,546N/A
3/31/2018366,90541,69525,78341,149N/A
12/31/2017354,76839,60216,77228,659N/A
9/30/2017342,29338,070N/A28,869N/A
6/30/2017330,62939,996N/A28,465N/A
3/31/2017320,34940,421N/A34,431N/A
12/31/2016309,69040,660N/A39,412N/A
9/30/2016302,00738,101N/A42,036N/A
6/30/2016292,76035,192N/A40,984N/A
3/31/2016275,17430,488N/A36,877N/A
12/31/2015259,93027,426N/A27,143N/A
9/30/2015244,76623,139N/A20,752N/A
6/30/2015234,68621,380N/A16,372N/A
3/31/2015228,19720,811N/A17,437N/A
12/31/2014226,01421,098N/A22,737N/A
9/30/2014224,39118,107N/A22,406N/A
6/30/2014220,61218,859N/A21,157N/A
3/31/2014218,09417,552N/A20,954N/A
12/31/2013213,08616,764N/A19,860N/A
9/30/2013206,33222,030N/A19,471N/A
6/30/2013201,69122,205N/A23,102N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: A086450's forecast earnings growth (16.2% per year) is above the savings rate (2.5%).

Earnings vs Market: A086450's earnings (16.2% per year) are forecast to grow slower than the KR market (28.4% per year).

High Growth Earnings: A086450's earnings are forecast to grow, but not significantly.

Revenue vs Market: A086450's revenue (9.7% per year) is forecast to grow faster than the KR market (9.1% per year).

High Growth Revenue: A086450's revenue (9.7% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: A086450's Return on Equity is forecast to be low in 3 years time (10.6%).


Discover growth companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.